Lataa...
Targeting mTOR for the treatment of B cell malignancies
Mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that functions as a key regulator of cell growth, division and survival. Many haematologic malignancies exhibit elevated or aberrant mTOR activation, supporting the launch of numerous clinical trials aimed at evaluating the potentia...
Tallennettuna:
| Julkaisussa: | Br J Clin Pharmacol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5061788/ https://ncbi.nlm.nih.gov/pubmed/26805380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12888 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|